Indivior Faces Stockholder Suits Over Merger Proxy, Bolsters Valuation Disclosures
INDV sits 60% above its 52-week low of $22.561.
Summary
Indivior disclosed that Supernus stockholders filed lawsuits over the merger proxy and that both companies voluntarily supplemented the proxy with additional valuation disclosures to avoid delaying the October 15 vote.
Updates
· SEC 425 — The 425 filing provides the same supplemental Cantor valuation disclosures as the 8-K, including Supernus implied per share range of $50.55 to $59.50 and Indivior dividend-adjusted range of $24.20 to $43.90.
- Selected Companies Analysis — Cantor adjusted for Supernus's estimated debt of $0; Supernus fully diluted shares were 60.3M-61.5M and Indivior 124.0M-139.3M as of July 28, 2026; Indivior's implied equity value was reduced by $1 billion special dividend.
- DCF Analysis
- Cantor's DCF analysis discounted values to June 30, 2026.
- Supernus DCF discount rates ranged from 9.5% to 11.5% (WACC, CAPM, size premium).
- Supernus DCF terminal value growth rates ranged from negative 10.0% to positive 3.0% after 2040.
- Supernus DCF adjusted for estimated present value of net operating losses and tax attributes after 2040.
- Supernus fully diluted shares for DCF analysis: 61.0 million to 61.7 million, as of July 28, 2026.
- Indivior DCF discount rates ranged from 8.0% to 10.0% (WACC, CAPM, size premium).
- Indivior DCF terminal value growth rates ranged from negative 10.0% to positive 3.0% after 2040.
- Indivior DCF adjusted for the $1 billion Special Dividend.
- Indivior fully diluted shares for DCF analysis: 124.0 million to 139.3 million, as of July 28, 2026.
- Contribution Analysis — Supernus fully diluted shares were approximately 60.8 million and Indivior approximately 124.0 million as of July 28, 2026.
- Precedent Transactions Analysis — Supernus fully diluted shares were 61.1M-62.1M and Indivior 124.0M-139.3M as of July 28, 2026; Indivior's implied equity value was reduced by $1 billion special dividend.
- Post-Merger Name — Indivior will be renamed Supernus, Inc. after the merger.
All 19 details
- Indivior will be renamed Supernus, Inc. after the merger.
- Cantor Fitzgerald adjusted for Supernus's estimated debt of $0 in selected companies analysis.
- Supernus fully diluted shares for selected companies analysis: 60.3M-61.5M, as of July 28, 2026.
- Indivior's implied equity value was reduced by $1 billion special dividend in selected companies analysis.
- Indivior fully diluted shares for selected companies analysis: 124.0M-139.3M, as of July 28, 2026.
- Cantor's DCF analysis discounted values to June 30, 2026.
- Supernus DCF discount rates ranged from 9.5% to 11.5% (WACC, CAPM, size premium).
- Supernus DCF terminal value growth rates ranged from negative 10.0% to positive 3.0% after 2040.
- Supernus DCF adjusted for estimated present value of net operating losses and tax attributes after 2040.
- Supernus fully diluted shares for DCF analysis: 61.0 million to 61.7 million, as of July 28, 2026.
- Indivior DCF discount rates ranged from 8.0% to 10.0% (WACC, CAPM, size premium).
- Indivior DCF terminal value growth rates ranged from negative 10.0% to positive 3.0% after 2040.
- Indivior DCF adjusted for the $1 billion Special Dividend.
- Indivior fully diluted shares for DCF analysis: 124.0 million to 139.3 million, as of July 28, 2026.
- Supernus fully diluted shares for contribution analysis: approximately 60.8 million, as of July 28, 2026.
- Indivior fully diluted shares for contribution analysis: approximately 124.0 million, as of July 28, 2026.
- Supernus fully diluted shares for precedent transactions analysis: 61.1M-62.1M, as of July 28, 2026.
- Indivior's implied equity value was reduced by $1 billion special dividend in precedent transactions analysis.
- Indivior fully diluted shares for precedent transactions analysis: 124.0M-139.3M, as of July 28, 2026.
Key Events · Legal and Risk Events · INDV
-
Stockholder Lawsuits Filed
Two complaints were filed by purported Supernus stockholders in New York state court alleging disclosure deficiencies in the merger proxy, along with demand letters from other stockholders.
-
Voluntary Supplemental Disclosures
Indivior and Supernus denied the allegations but voluntarily supplemented the proxy with additional Cantor Fitzgerald valuation details, including Supernus cash of ~$372M and Indivior cash of ~$249M and debt of ~$500M.
-
Valuation Ranges Disclosed
Cantor's DCF analysis indicated an implied per share equity value range of $50.55 to $59.50 for Supernus and a dividend-adjusted range of $24.20 to $43.90 for Indivior.
-
Merger Vote Still Scheduled
The special meetings of Indivior and Supernus stockholders remain scheduled for October 15, 2026, with the companies aiming to moot the litigation to avoid delay.
Analysis · INDV · Life Sciences
Two Supernus stockholders have filed complaints in New York state court alleging the merger proxy contained disclosure deficiencies. While Indivior and Supernus deny the claims, they voluntarily supplemented the proxy with additional Cantor Fitzgerald valuation details—including specific cash, debt, and share count figures—to avoid delaying the October 15 shareholder vote. The litigation adds uncertainty to the merger timeline, though the companies are actively working to moot the claims.
How filings like this one have moved
In the 30 days to Oct 6, 2026, 28.9% of the 1573 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INDV was trading at $35.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $22.56 to $42.81. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.